HealthTop Stories

Seizures Can Now Be Curbed Using A New Implantable Device

The seizures are a common condition following a certain set of diseases. It is quite difficult for the patients dealing with it as the time and duration of the condition is something tricky to guess. Thus, a group of researchers has developed a protein-secreting device which can be implanted into the hippocampus. Presently, as it is in the preclinical trial it has been integrated into the hippocampus of the epileptic rats and the results are flooring as 93% reduction within 3 Months in the seizure attacks was observed. Currently, the development of this technology is being encouraged in order to stand out as a next-generation treatment for epilepsy.

This device is a creation of the present need for potentially effective and well-sustainable epilepsy therapies.  The University of Ferrara and of Gloriana Therapeutics, Inc. researchers have together planned on scrutinizing the Gloriana targeted cellular delivery system’s effect for the glial cell line-derived neurotrophic factor (GDNF), which is a protein believed to help curb the epileptic activity. The researchers have found their new device to help reduce the seizures and also the anxiety-like symptoms with a better performance in the recognition task directing towards improved cognition.

One of the amazing features is that the treatment helped reduce or even correct the abnormalities in brain anatomy connected with epilepsy. The best part of the device is that even after it is removed the effects still persist indicating that the disease progression can still be modified despite the removal of the implant. A group of researchers headed by Ashok K. Shetty from the Texas A&M College of Medicine are working on finding a permanent cure for epilepsy. About 3.4 Million Americans are having epilepsy and majority of which respond to the anti-seizure medications being consumed but still have seizures. These can cause memory loss, depression, and cognitive problems. The scientists developed induced pluripotent stem cells from the skin cells and further coaxed it to produce GABAergic progenitor cells which can be transplanted into the hippocampus of early temporal lobe epilepsy patients.

Show More

Ashley Johnson

Ashley Johnson has a Bachelor’s Degree in Medicines. With an experience of more than 4 years, she has a good reputation at ZMR Industry Journal and is known for her punctuality. With no doubt, Ashley is the perfect choice to spearhead the Health department. It is she who looks after each published article in this domain. Even the slightest change must be approved by her. In her free time, Ashley will be seen playing and cuddling with her dog, who she loves than anybody else.

Related Articles